1,4,8,11-tetraazacyclohexadecane | 85828-16-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,4,8,11-tetraazacyclohexadecane
• 英文别名: 1,4,8,11-tetrazacyclohexadecane
• CAS: 85828-16-6
• 化学式: C₁₂H₂₈N₄
• 分子量: 228.381
• InChiKey: LVUJYLFNBHQPKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  48.1
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  copper(II) perchlorate hexahydrate 、 1,4,8,11-tetraazacyclohexadecane 在 高氯酸 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Bembi, Ramesh; Bhardwarj, Virendra K.; Singh, Randhir, Inorganic Chemistry, 1984, vol. 23, # 25, p. 4153 - 4157

  摘要：

  DOI：

文献信息

• [EN] COCRYSTALS OF PTEROSTILBENE AND COMPOSITIONS COMPRISING THEM<br/>[FR] CO-CRISTAUX DE PTÉROSTILBÈNE ET COMPOSITIONS COMPRENANT CEUX-CI
  申请人：CENTER FOR INTELLIGENT RES IN CRYSTAL ENGINEERING S L

  公开号：WO2021123162A1

  公开（公告）日：2021-06-24

  The present disclosure relates to a cocrystal of pterostilbene and a coformer capable to form hydrogen bond interactions, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The present disclosure also relates to a composition comprising the cocrystal.

  本公开涉及一种可形成氢键相互作用的紫檀酸甲酯和共晶体形成物，其制备过程及其作为药物或膳食补充剂的用途。本公开还涉及包含该共晶体的组合物。
• Synthesis and Characterization of<i>trans</i>[CoCl₂(232N₄<i>x</i>)]⁺(232N₄<i>x</i>= 1,4,8,11Tetraazacyclopentadecane, -cyclohexadecane, -cycloheptadecane, -cyclooctadecane, -cyclononadecane, -cycloicosane, -cyclohenicosane, and -cyclotricosane)
  作者：Masanobu Tsuchimoto、Yasuhiro Ito、Junnosuke Fujita

  DOI：10.1246/bcsj.68.866

  日期：1995.3

  Five new macrocyclic ligands which form a large (10—15) chelate ring upon coordination (1,4,8,11-tetraazacyclooctadecane(232N410), -cyclononadecane(232N411), -cycloicosane (232N412), -cyclohenicosane(232N413), and -cyclotricosane(232N415)), and the Co(III) complexes, trans-[CoCl2(232N4x)]+ (x = 7—13, 15) were prepared and characterized. Of six isomers arising from the combination of four chiral nitrogen donor atoms in this type of complex, three and two isomers were obtained, respectively, for complexes with x = 7 and 8, and x = 9—13 and 15. The ligand field parameter of the nitrogen donor atom (Δ(N)) of 232N4x decreases largely from x = 6 to 7, and then shows a small fluctuation with a small decrease at x = even-numbers and a small increase at x = odd-numbers, while a smaller change is observed for the parameter of the chloride ion (Δ(Cl)). The reduction potential for the Co(III)/Co(II) couple (E1/2) shifts to the positive side from the complex with x = 6 to those with x = 7 and 8, and then shows a small change depending on the ring members. The ΔEp(Epa − Epc) values of complexes with x = 8—11 are large, indicating an instability of the medium-sized chelate Co(II) complexes.

  五种新的大环配体（1,4,8,11-tetraazacyclooctadecane(232N410), -cyclononadecane(232N411)、(232N410)、-环十一烷(232N411)、-环二十烷(232N412)、-环二十三烷(232N413)和-环三萜(232N415))以及 Co(III) 复合物反式-[CoCl2(232N4x)]+ (x = 7-13, 15)的制备和表征。这类配合物中四个手性氮供体原子的组合产生了六种异构体，其中 x = 7 和 8、x = 9-13 和 15 的配合物分别得到了三种和两种异构体。232N4x 的氮供体原子配体场参数（Δ(N)）从 x = 6 到 7 时大幅度下降，然后出现小幅波动，x = 偶数时小幅下降，x = 奇数时小幅上升，而氯离子参数（Δ(Cl)）的变化较小。从 x = 6 的复合物到 x = 7 和 8 的复合物，Co(III)/Co(II)偶联物的还原电位（E1/2）向正侧移动，然后根据环成员的不同而发生微小变化。x = 8-11 的配合物的ΔEp（Epa - Epc）值较大，表明中等大小的螯合 Co(II) 配合物不稳定。
• Methods for enhancing the efficacy of vascular disrupting agents
  申请人：Kerbel Robert

  公开号：US20080214509A1

  公开（公告）日：2008-09-04

  This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Antagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF-1 antagonist) sequentially or simultaneously in combination with said Vascular Disrupting Agent.
• [EN] METHODS FOR ENHANCING THE EFFICACY OF VASCULAR DISRUPTING AGENTS<br/>[FR] PROCÉDÉS D'AMÉLIORATION DE L'EFFICACITÉ D'AGENTS VASCULOTOXIQUES
  申请人：OXIGENE INC

  公开号：WO2008109076A1

  公开（公告）日：2008-09-12

  [EN] This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhacing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Angtagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF- 1 antagonist) sequentially or simultaneously in combination with said Vascular Disrupting Agent.
  [FR] La présente invention concerne des procédés de traitement, de prévention et/ou de gestion du cancer chez un sujet, qui comprennent l'amélioration de l'efficacité d'un agent vasculotoxique (par exemple, une combrétastatine ou un de ses dérivés) en administrant au sujet un antagoniste de récepteur de chimiokine (par exemple, un antagoniste du CXCR4) ou un antagoniste de chimiokine (par exemple, un antagoniste de la SDF-1) à la suite ou simultanément en association avec ledit agent vasculotoxique.
• Bembi, Ramesh; Bhardwarj, Virendra K.; Singh, Randhir, Inorganic Chemistry, 1984, vol. 23, # 25, p. 4153 - 4157
  作者：Bembi, Ramesh、Bhardwarj, Virendra K.、Singh, Randhir、Singh, Rakam、Taneja, Kapil、Aftab, Shabana

  DOI：——

  日期：——